Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Nov 27:2023.11.27.23298990.
doi: 10.1101/2023.11.27.23298990.

A Modified Mediterranean Ketogenic Diet mitigates modifiable risk factors of Alzheimer's Disease: a serum and CSF-based metabolic analysis

Affiliations

A Modified Mediterranean Ketogenic Diet mitigates modifiable risk factors of Alzheimer's Disease: a serum and CSF-based metabolic analysis

Annalise Schweickart et al. medRxiv. .

Update in

Abstract

Alzheimer's disease (AD) is influenced by a variety of modifiable risk factors, including a person's dietary habits. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored KD's metabolic impact, especially on blood and cerebrospinal fluid (CSF). Our study involved participants at risk for AD, either cognitively normal or with mild cognitive impairment. The participants consumed both a modified Mediterranean-ketogenic diet (MMKD) and the American Heart Association diet (AHAD) for 6 weeks each, separated by a 6-week washout period. We employed nuclear magnetic resonance (NMR)-based metabolomics to profile serum and CSF and metagenomics profiling on fecal samples. While the AHAD induced no notable metabolic changes, MMKD led to significant alterations in both serum and CSF. These changes included improved modifiable risk factors, like increased HDL-C and reduced BMI, reversed serum metabolic disturbances linked to AD such as a microbiome-mediated increase in valine levels, and a reduction in systemic inflammation. Additionally, the MMKD was linked to increased amino acid levels in the CSF, a breakdown of branched-chain amino acids (BCAAs), and decreased valine levels. Importantly, we observed a strong correlation between metabolic changes in the CSF and serum, suggesting a systemic regulation of metabolism. Our findings highlight that MMKD can improve AD-related risk factors, reverse some metabolic disturbances associated with AD, and align metabolic changes across the blood-CSF barrier.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr. Krumsiek holds equity in Chymia LLC and iollo, owns intellectual property in PsyProtix, and serves as an advisor for celeste. Annalise Schweickart is a co-founder of celeste. Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix.

Figures

Figure 1:
Figure 1:. Cross-over design of the diet study:
In the study, 20 participants were enrolled. They were randomized into two groups: one followed the modified Mediterranean ketogenic diet (MMKD) and the other followed the American Heart Association diet (AHAD). Each group adhered to their respective diet for 6 weeks, followed by a 6-week washout period, after which they switched to the other diet. Throughout the study, samples from cerebrospinal fluid (CSF), serum, and microbiome were collected from each participant at various time points.
Figure 2:
Figure 2:. Serum metabolite associated with the modified Mediterranean ketogenic diet (MMKD).
a. Fold change of significantly altered metabolites after 6 weeks on MMKD (n = 19). The arrows next to the metabolite names indicate the effect direction of these metabolites in dementia or AD based on the UKBB cohort. b. Changes in the levels of the three branched-chain amino acids (BCAAs) pre- and post-diet. Each line represents the trend in a single individual. c. i) Microbiome species that show differential abundance by diet and are significantly correlated with serum BCAA (p = 3.9e-13). ii) Species whose genome encodes BCAA biosynthesis have a significantly higher association to serum BCAA and are significantly more enriched post-MMKD as compared to AHAD. d. Pre- and post-diet changes in total HDL and size-specific HDL particle concentrations, cholesterol ester, and free cholesterol content (mmol/l). Abbreviations: HDL = high-density lipoprotein, PLs = phospholipids, CEs = cholesteryl esters, VLDL = very low-density lipoprotein, FC = free cholesterol, C = cholesterol, TGs = triglycerides, PGs= phosphoglycerides, SFAs = saturated fatty acids, FA = fatty acids, BCAAs = branched-chain amino acids.
Figure 3:
Figure 3:. CSF metabolites associated with the modified Mediterranean ketogenic diet (MMKD).
a. Fold change of significantly altered metabolites after 6 weeks on MMKD (n = 19) with 95% confidence interval. Light blue circles represent the metabolites altered in CSF. The corresponding change of each metabolite measured in serum is shown in red. b. BCAA metabolism network with MMKD-altered metabolites colored to reflect effect direction. Blue represents a decrease post-diet, red represents an increase post-diet, black represents unchanged, and brown represents unavailable measurements. Dotted lines indicate the presence of intermediate steps between two metabolites, while solid lines are a direct conversion.
Figure 4:
Figure 4:. Bipartite graph between CSF and serum metabolites.
Each node represents a metabolite. Ellipses depict metabolites measured in serum, and diamonds represent metabolites measured in CSF. Each edge represents a significant (FDR < 5%) correlation of the magnitude of changes pre- to post-diet between two metabolites. Node color represents their biochemical groups.

References

    1. Hampel H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639–652 (2018). - PMC - PubMed
    1. 2022 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 18, 700–789 (2022). - PubMed
    1. Golde T. E. Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers. Neurotherapeutics 19, 209–227 (2022). - PMC - PubMed
    1. Dhillon S. Aducanumab: First Approval. Drugs 81, 1437–1443 (2021). - PubMed
    1. Shi M., Chu F., Zhu F. & Zhu J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging Neuroscience 14, (2022). - PMC - PubMed

Publication types

LinkOut - more resources